Clinical immunogenicity of the d -amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments
Mark A. Kroenke(Amgen (United States)), M. Benjamin Hock(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Benjamin Wu(Amgen (United States)), Bethlyn Sloey(Amgen (United States)), Hongjie Deng(North Sichuan Medical University), Michael Serenko(Amgen (United States)), Dohan Weeraratne(Amgen (United States))
Cited by 19
Related Papers
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications
|Clinical Pharmacokinetics|2016|213
Comparison of Information-Dependent Acquisition, SWATH, and MS<sup>All</sup> Techniques in Metabolite Identification Study Employing Ultrahigh-Performance Liquid Chromatography–Quadrupole Time-of-Flight Mass Spectrometry
|Analytical Chemistry|2013|211
Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry
|Journal of Mass Spectrometry|2006|153